DB-OTO
DB-OTO-001
Phase 2 small_molecule active
Quick answer
DB-OTO for Congenital Hearing Loss Secondary to Biallelic Pathogenic Variants of the Otoferlin Gene (OTOF) is a Phase 2 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Congenital Hearing Loss Secondary to Biallelic Pathogenic Variants of the Otoferlin Gene (OTOF)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active